Safety of Certolizumab Pegol in Chronic Plaque Psoriasis: Cumulative Data Over 48 Weeks’ Exposure from Phase 3, Multicenter, Randomized, Placebo-Controlled Studies. J of Skin 2018, 2 (S1), S16. https://doi.org/10.25251/skin.2.supp.16.